BioCentury | Dec 23, 2020
Finance

NASDAQ IPOs’ class of 2020 far outpaces prior years: Data Byte

...neither conducted a traditional IPO. Neuroscience company Yumanity Therapeutics...
BioCentury | Aug 25, 2020
Deals

Reverse merger offers Yumanity faster, less risky path to NASDAQ

...Therapeutics Inc. (NASDAQ:PTI) that will result in Yumanity Therapeutics LLC...
...to $1.36 on Monday.TARGETSSCD1 —Stearoyl-CoA desaturase-1 Virginia Li Yumanity Therapeutics LLC Tony...
BioCentury | Jul 30, 2020
Finance

With biggest biotech SPAC merger yet, Cerevel’s public path could augur more deals in same vein

...and listing, Chairman and CEO Tony Coles told BioCentury. Coles joined Cerevel in September from Yumanity Therapeutics LLC...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

...two neuro programs Merck & Co. Inc. (NYSE:MRK) licensed exclusive rights to two programs from Yumanity Therapeutics LLC...
...Writer Tetraphase Pharmaceuticals Inc. La Jolla Pharmaceutical Co. Melinta Therapeutics Inc. AcelRx Pharmaceuticals Inc. Century Therapeutics LLC Empirica Therapeutics Compass Therapeutics Editas Medicine Inc. Yumanity Therapeutics LLC Merck...
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...for the new position of SVP, therapeutics discovery. He co-founded and served as CSO of Yumanity Therapeutics LLC...
BioCentury | Nov 20, 2019
Company News

Management tracks: Vifor, Relay, I-Mab, Yumanity, Savara and more

...CEO. Shen succeeds founder Jingwu Zang, who remains chairman of the immunology company. Neurodegeneration company Yumanity Therapeutics LLC...
...She was the executive medical director of vaccine R&D at CRO Pharmaceutical Product Development LLC. BioCentury Staff Yumanity Therapeutics LLC Savara...
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...the venture arm of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Lucas was senior director of chemistry at Yumanity Therapeutics LLC...
BioCentury | Sep 11, 2019
Product Development

Pharmas’ challenge: learning from rare disease units while leaving them alone

...head of rare diseases at Sanofi from 2015-17. He is now CEO of neurology company Yumanity Therapeutics LLC...
...Tarrytown, N.Y. Sanofi (Euronext:SAN; NASDAQ:SNY), Paris, France Takeda Pharmaceutical Co. Ltd. (JASDAQ:4502; NYSE:TAK), Tokyo, Japan Yumanity Therapeutics LLC...
BioCentury | Sep 9, 2019
Company News

Management tracks: Coles to lead Cerevel; plus Genfit, Jubilant, Paratek, Mogrify, Dementia Discovery Fund and Ayala

...is Cerevel’s executive chairman as well as the co-founder and executive chairman of neurodegeneration company Yumanity Therapeutics LLC...
...Inc. (NYSE:ABBV). BC Staff Ayala Pharmaceuticals Inc. Cerevel Therapeutics LLC Dementia Discovery Fund Genfit S.A. Jubilant Life Sciences Ltd. Mogrify Ltd. Paratek Pharmaceuticals Inc. Yumanity Therapeutics LLC Jubilant...
BioCentury | Jul 10, 2019
Company News

Yumanity’s Coles picks Merrimack, Onyx alum Peters to lead company to the clinic

...which generated at least eight neurodegeneration targets since the company's launch in 2014. Coles co-founded Yumanity Therapeutics LLC...
...looking for a new project, yet. The appointment takes effect on Sept 3. Lauren Martz, Associate Editor Yumanity Therapeutics LLC Stearoyl-CoA...
Items per page:
1 - 10 of 30
BioCentury | Dec 23, 2020
Finance

NASDAQ IPOs’ class of 2020 far outpaces prior years: Data Byte

...neither conducted a traditional IPO. Neuroscience company Yumanity Therapeutics...
BioCentury | Aug 25, 2020
Deals

Reverse merger offers Yumanity faster, less risky path to NASDAQ

...Therapeutics Inc. (NASDAQ:PTI) that will result in Yumanity Therapeutics LLC...
...to $1.36 on Monday.TARGETSSCD1 —Stearoyl-CoA desaturase-1 Virginia Li Yumanity Therapeutics LLC Tony...
BioCentury | Jul 30, 2020
Finance

With biggest biotech SPAC merger yet, Cerevel’s public path could augur more deals in same vein

...and listing, Chairman and CEO Tony Coles told BioCentury. Coles joined Cerevel in September from Yumanity Therapeutics LLC...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

...two neuro programs Merck & Co. Inc. (NYSE:MRK) licensed exclusive rights to two programs from Yumanity Therapeutics LLC...
...Writer Tetraphase Pharmaceuticals Inc. La Jolla Pharmaceutical Co. Melinta Therapeutics Inc. AcelRx Pharmaceuticals Inc. Century Therapeutics LLC Empirica Therapeutics Compass Therapeutics Editas Medicine Inc. Yumanity Therapeutics LLC Merck...
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...for the new position of SVP, therapeutics discovery. He co-founded and served as CSO of Yumanity Therapeutics LLC...
BioCentury | Nov 20, 2019
Company News

Management tracks: Vifor, Relay, I-Mab, Yumanity, Savara and more

...CEO. Shen succeeds founder Jingwu Zang, who remains chairman of the immunology company. Neurodegeneration company Yumanity Therapeutics LLC...
...She was the executive medical director of vaccine R&D at CRO Pharmaceutical Product Development LLC. BioCentury Staff Yumanity Therapeutics LLC Savara...
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...the venture arm of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Lucas was senior director of chemistry at Yumanity Therapeutics LLC...
BioCentury | Sep 11, 2019
Product Development

Pharmas’ challenge: learning from rare disease units while leaving them alone

...head of rare diseases at Sanofi from 2015-17. He is now CEO of neurology company Yumanity Therapeutics LLC...
...Tarrytown, N.Y. Sanofi (Euronext:SAN; NASDAQ:SNY), Paris, France Takeda Pharmaceutical Co. Ltd. (JASDAQ:4502; NYSE:TAK), Tokyo, Japan Yumanity Therapeutics LLC...
BioCentury | Sep 9, 2019
Company News

Management tracks: Coles to lead Cerevel; plus Genfit, Jubilant, Paratek, Mogrify, Dementia Discovery Fund and Ayala

...is Cerevel’s executive chairman as well as the co-founder and executive chairman of neurodegeneration company Yumanity Therapeutics LLC...
...Inc. (NYSE:ABBV). BC Staff Ayala Pharmaceuticals Inc. Cerevel Therapeutics LLC Dementia Discovery Fund Genfit S.A. Jubilant Life Sciences Ltd. Mogrify Ltd. Paratek Pharmaceuticals Inc. Yumanity Therapeutics LLC Jubilant...
BioCentury | Jul 10, 2019
Company News

Yumanity’s Coles picks Merrimack, Onyx alum Peters to lead company to the clinic

...which generated at least eight neurodegeneration targets since the company's launch in 2014. Coles co-founded Yumanity Therapeutics LLC...
...looking for a new project, yet. The appointment takes effect on Sept 3. Lauren Martz, Associate Editor Yumanity Therapeutics LLC Stearoyl-CoA...
Items per page:
1 - 10 of 30